MOLECULIN BIOTECH INC (MBRX) Institutional Ownership Changes & 13F Activity
MOLECULIN BIOTECH INC (MBRX). Institutional ownership data tracks hedge funds, asset managers, and other institutional investors based on recent SEC Form 13F filings (Q2 2026). This page analyzes institutional buying and selling activity, new holdings, and sold-out positions in the latest reporting period. Notable filers include Sabby Management, Llc, Vanguard Capital Management Llc, Vanguard Fiduciary Trust Co, Xtx Topco Ltd, and Morgan Stanley.
| Institution | Type | Change in shares | Change Position % | Shares | Reported stock balance | Portfolio quarter | Filing date |
|---|---|---|---|---|---|---|---|
| Xtx Topco Ltd | Buy | +22,942 | — | 22,942 | $64.01K | Q2 2026 | Aug 14, 2026 |
| Barclays Plc | Buy | +621 | — | 621 | $1.73K | Q2 2026 | Aug 14, 2026 |
| Jones Financial Companies Lllp | Buy | +360 | — | 360 | $1.18K | Q2 2026 | Aug 14, 2026 |
| Wells Fargo & Company/Mn | Buy | +200 | — | 200 | $558.00 | Q2 2026 | Aug 14, 2026 |
| Vanguard Capital Management Llc | Buy | +28,346 | +204.4% | 42,215 | $117.78K | Q2 2026 | Aug 13, 2026 |
| Vanguard Fiduciary Trust Co | Buy | +23,811 | +392.1% | 29,883 | $83.37K | Q2 2026 | Aug 13, 2026 |
| Morgan Stanley | Buy | +20,000 | +55555.6% | 20,036 | $55.90K | Q2 2026 | Aug 13, 2026 |
| Rockefeller Capital Management L.P. | Buy | +10,579 | +239.3% | 15,000 | $41.85K | Q2 2026 | Aug 13, 2026 |
| Geode Capital Management, Llc | Buy | +14,923 | +46.2% | 47,252 | $131.83K | Q2 2026 | Aug 12, 2026 |
| Tower Research Capital Llc (Trc) | Buy | +1,679 | +91.5% | 3,514 | $9.80K | Q2 2026 | Aug 11, 2026 |
| Citigroup Inc | Buy | +2,674 | — | 2,674 | $7.46K | Q2 2026 | Aug 03, 2026 |
| Sbi Securities Co., Ltd. | Buy | +1 | +2.3% | 44 | $123.00 | Q2 2026 | Jul 23, 2026 |
| Sabby Management, Llc | Sell | -75,021 | -100.0% | 0 | $0.00 | Q2 2026 | May 15, 2026 |
| Fmr Llc | Sell | -3 | -100.0% | 0 | $0.00 | Q2 2026 | May 15, 2026 |
| Hrt Financial Lp | Sell | -13,739 | -100.0% | 0 | $0.00 | Q2 2026 | May 14, 2026 |
| Pinnacle Wealth Planning Services, Inc. | Sell | -281 | -100.0% | 0 | $0.00 | Q2 2026 | May 11, 2026 |
| Caitong International Asset Management Co., Ltd | Sell | -2 | -100.0% | 0 | $0.00 | Q2 2026 | May 11, 2026 |
| Vanguard Global Advisers, Llc | Sell | -24 | -100.0% | 0 | $0.00 | Q2 2026 | May 08, 2026 |
| Ubs Group Ag | Sell | -3,409 | -100.0% | 0 | $0.00 | Q2 2026 | May 05, 2026 |
Frequently asked questions about MBRX activity
Which institutional owners are buying MBRX?
Institutional owners buying MBRX include investors who have either initiated new positions or increased their existing holdings based on recent SEC 13F filings. The activity table above highlights which funds added shares in the latest reporting periods and how their positions changed over time.
What does "buy" mean in MBRX activity?
"Buy" means an investor increased their reported position in MBRX compared to the prior reporting period. This reflects growing exposure to MOLECULIN BIOTECH INC (MBRX) rather than necessarily a brand-new position (though new positions also appear as buys when prior quantity was zero).
Is institutional interest in MBRX increasing?
Institutional interest in MBRX can be assessed by comparing the number of tracked funds adding or increasing positions versus those trimming or exiting across the periods shown. A higher number of additions typically signals increasing participation among large filers, but it should be read alongside position sizes and the full table.